Drawing for LENTINAN XP

USPTO serial 77332691

LENTINAN XP

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
CASE, LEIGH CAROLINE
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with LENTINAN XP?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Robert J. Metzler II

ROBERT J. METZLER II TYLER COOPER & ALCORN, LLP185 ASYLUM STREETCITYPLACE I - 35TH FLOORHARTFORD, CT 06103-3488

Goods and services

ClassDescriptionStatusFirst use
005PHARMACEUTICAL PREPARATIONS, NAMELY, PREPARATIONS FOR NEOPLASTIC DISEASES SUCH AS CANCERS, LIVER DISEASES, DIABETES, ALLERGIES, AIDS, SKIN DISEASES, ELEVATED BLOOD PRESSURE, ELEVATED CHOLESTEROL, CHRONIC BRONCHITIS, PHLEBITIS AND THROMBOSIS; DIETETIC PREPARATIONS ADAPTED FOR MEDICAL USE, NAMELY, DIETARY SUPPLEMENTS, DIET PILLS, DIET CAPSULES, POWDER PRODUCTS, NAMELY, POWDERED NUTRITIONAL SUPPLEMENT DRINK MIX; PHARMACEUTICAL PREPARATIONS, NAMELY, ANTICANCER PREPARATIONS, PREPARATIONS FOR THE TREATMENT OF LIVER DISEASES, DIABETES, ALLERGIES, AIDS, SKIN DISEASES, ELEVATED BLOOD PRESSURE, ELEVATED CHOLESTEROL, CHRONIC BRONCHITIS, PHLEBITIS AND THROMBOSIS; FOOD SUPPLEMENTS; NUTRACEUTICALS FOR THE TREATMENT OF CANCERS, LIVER DISEASES, DIABETES, ALLERGIES, AIDS, SKIN DISEASES, ELEVATED BLOOD PRESSURE, ELEVATED CHOLESTEROL, CHRONIC BRONCHITIS, PHLEBITIS AND THROMBOSIS; MEDICAL MUSHROOM INGREDIENTS FOR USE IN THE PHARMACEUTICAL INDUSTRIES, NAMELY, SHII-TAKE FUNGI; PROCESSED SHIITAKE MUSHROOMS FOR MEDICINAL OR THERAPEUTIC PURPOSES; MUSHROOM-BASED PHARMACEUTICALS FOR THE TREATMENT OF LIVER DISEASES, DIABETES, ALLERGIES, AIDS, SKIN DISEASES, ELEVATED BLOOD PRESSURE, ELEVATED CHOLESTEROL, CHRONIC BRONCHITIS, PHLEBITIS AND THROMBOSIS; IMMUNOSTIMULANTS FOR THE PURPOSE OF IMPROVING SURVIVAL, GROWTH AND MODULATING THE MICROBIAL POPULATION IN THE DIGESTIVE TRACT; FUNCTIONAL FOOD WITH A HEALTH BENEFICIAL OR DISEASE PREVENTATIVE EFFECT, NAMELY, FOOD SUPPLEMENTS, MAINLY CONSISTING OF PROCESSED SHIITAKE MUSHROOMS FOR MEDICINAL OR THERAPEUTIC PURPOSESACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Mar 15, 2010MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 15, 2010ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 17, 2009EX1GSOU EXTENSION 1 GRANTED—
Aug 12, 2009AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jul 13, 2009EXT1SOU EXTENSION 1 FILED—
Jul 13, 2009MAILPAPER RECEIVED—
May 29, 2009DOCKASSIGNED TO EXAMINER—
Feb 10, 2009NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 18, 2008PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 29, 2008NPUBNOTICE OF PUBLICATION—
Oct 14, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Oct 7, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 21, 2008TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 21, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 17, 2008ALIEASSIGNED TO LIE—
Sep 10, 2008TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 11, 2008GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 11, 2008GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 11, 2008CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 4, 2008DOCKASSIGNED TO EXAMINER—
Nov 23, 2007NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance